Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
Mobitz, H., Machauer, R., Holzer, P., Vaupel, A., Stauffer, F., Ragot, C., Caravatti, G., Scheufler, C., Fernandez, C., Hommel, U., Tiedt, R., Beyer, K.S., Chen, C., Zhu, H., Gaul, C.(2017) ACS Med Chem Lett 8: 338-343
- PubMed: 28337327 
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00519
- Primary Citation of Related Structures:  
5MVS, 5MW3, 5MW4 - PubMed Abstract: 
Misdirected catalytic activity of histone methyltransferase Dot1L is believed to be causative for a subset of highly aggressive acute leukemias. Targeting the catalytic domain of Dot1L represents a potential therapeutic approach for these leukemias. In the context of a comprehensive Dot1L hit finding strategy, a knowledge-based virtual screen of the Dot1L SAM binding pocket led to the discovery of 2 , a non-nucleoside fragment mimicking key interactions of SAM bound to Dot1L. Fragment linking of 2 and 3 , an induced back pocket binder identified in earlier studies, followed by careful ligand optimization led to the identification of 7 , a highly potent, selective and structurally novel Dot1L inhibitor.
Organizational Affiliation: 
Novartis Institutes for Biomedical Research , 4002 Basel, Switzerland.